Subtitle: Market Intelligence, Clinical Progress, and High-Purity Reagents for Leukemia and Hematological Malignancy Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for NUP98-NUP96/NUP98 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | NUP98 Recombinant Protein (FG-Repeat Domain / Full Length) High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. E. coli or Mammalian expressed. |
View NUP98 Products |
| Gene Delivery | NUP98 / NUP98-Fusion Promise-ORF / Lentivirus Full-length ORF and clinical fusion variants (e.g., NUP98-HOXA9, NUP98-KDM5A) for stable cell lines. |
View NUP98 Products |
| Benchmark Ab | Anti-NUP98 Recombinant Antibody Recombinant positive control for Western Blot, IHC, and Immunofluorescence. |
View NUP98 Products |
| Validator | NUP98 siRNA Set For knockdown verification and target specificity assays. |
View NUP98 Products |
| Related Target A | HOXA9 Downstream transcription factor frequently upregulated by NUP98 fusions; critical read-out for therapeutic efficacy. |
View HOXA9 Products |
| Related Target B | KDM5A Epigenetic reader partnering in NUP98-KDM5A fusions; target for disrupting oncogenic chromatin binding. |
View KDM5A Products |
| Related Target C | MEN1 (Menin) Essential cofactor in the MLL/NUP98 leukemia transcription complex; target for small-molecule inhibitors. |
View MEN1 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Intrinsically Disordered Region (IDR) Aggregation | NUP98 FG-repeat domains are purified under optimized buffer conditions to prevent non-specific aggregation; monomeric state verified by SEC-MALS. |
| Fusion Protein Modeling in Vitro | Lentivirus-premade particles encoding major NUP98 fusions (HOXA9, NSD1) enable stable, native-conformation expression in human hematopoietic lineages. |
| Lack of Controls | Sequence-verified clinical benchmark antibodies and recombinant positive controls included. |
| False Positives in Small Molecule Screens | Target-specific siRNA knockdown sets included for rigorous validation of phenotypic drug responses. |
Live NUP98-NUP96 / NUP98 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The therapeutic targeting of NUP98 and its oncogenic fusions (e.g., NUP98-NSD1, NUP98-KDM5A) represents a frontier in hard-to-treat hematological malignancies, including acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). The race for NUP98-associated therapeutics is intensifying, with major players shifting focus from traditional cytotoxic regimens to small-molecule inhibitors of epigenetic adaptors (like Menin and WDR5) and targeted protein degraders (PROTACs). As first-generation indirect therapies reach advanced clinical phases, the next wave of R&D is targeting the physical phase-separation properties of NUP98 FG-repeats and direct fusion protein degradation.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule (Menin/WDR5 Inhibitors) | Syndax Pharmaceuticals, Kura Oncology | NUP98-rearranged AML, NPM1-mutant AML | Disruption Assay (Need high-purity recombinant NUP98 fusion complexes) |
| Targeted Protein Degraders (PROTACs) | Academic Consortia, Biotech Startups | Refractory Myeloid Leukemias | Degradation Kinetics (Need Lentivirus for stable GFP-NUP98 fusion expression) |
| Transcription / Phase-Separation Blockers | Pre-clinical Biotechs | Pediatric AML, T-ALL | In vitro Condensation Assay (Need monomeric, high-purity FG-repeat proteins) |